SSA
TRML

Schonfeld Strategic Advisors’s Tourmaline Bio TRML Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-353,514
Closed -$5.65M – 2591
2025
Q2 		$5.65M Buy
353,514
+53,775
+18% +$871K 0.04% 532
2025
Q1 		$4.56M Buy
299,739
+1,500
+0.5% +$24K 0.03% 556
2024
Q4 		$6.05M Buy
298,239
+100,139
+51% +$2.52M 0.04% 436
2024
Q3 		$5.09M Buy
198,100
+43,669
+28% +$729K 0.03% 535
2024
Q2 		$1.99M Sell
154,431
-27,529
-15% -$443K 0.01% 915
2024
Q1 		$4.17M Buy
+181,960
New +$6.42M 0.03% 718

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Schonfeld Strategic Advisors's TRML Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 353,514 shares — an estimated $5.65M sold.

Schonfeld Strategic Advisors first reported a position in TRML in Q1 2024 and held it in 6 quarters. The position peaked at $6.05M in Q4 2024. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 353,514 Tourmaline Bio shares in Q3 2025, an estimated $5.65M.
  • Schonfeld Strategic Advisors first reported a position in Tourmaline Bio in Q1 2024 and held it in 6 quarters.
  • Schonfeld Strategic Advisors's Tourmaline Bio position peaked at $6.05M in Q4 2024.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.